Psoriatic Arthritis – Epidemiology – Americas
Clarivate Epidemiology's coverage of psoriatic arthritis (PsA) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of PsA for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan, and 10 years for the other countries covered in this report.
Clarivate Epidemiology's PsA forecast will answer the following questions:
- Of all people with PsA, how many in each country across the major mature pharmaceutical markets have been formally diagnosed?
- Of all people diagnosed with PsA, how many in each country across the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of PsA over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts four PsA patient populations, as follows:
- Total PsA prevalent cases.
- Total PsA prevalent cases with peripheral joint involvement.
- Total PsA prevalent cases with axial joint involvement.
- Total PsA prevalent cases with mixed joint involvement.
Note: Coverage may vary by country.
Table of contents
- Psoriatic Arthritis - Epidemiology - Americas
- Epidemiology Data
- Methods
- Literature review (studies included in / excluded from the analyses of psoriatic arthritis)
- Total prevalent cases
- Diagnosed Prevalent Cases
- Diagnosed Drug-Treated Prevalent Cases
- Total prevalent cases by joint involvement
- Risk / protective factors applied to disease forecast models
- Reference Materials
- Bibliography
- Glossary
- Abbreviations
Navya Vardhan, M.Sc., is an associate epidemiologist at Clarivate. She obtained her M.Sc. in biostatistics and demography from the International Institute for Population Sciences in Mumbai. She also holds a B.Sc. in mathematics.
Stephanie Niquita Phankon, M.B.B.S., M.P.H., is a senior epidemiologist at Clarivate. She trained as a community physician and has supervised and coordinated various governmental and nongovernmental public health projects. She holds an M.P.H. specializing in epidemiology from the Tata Institute of Social Sciences in Mumbai and a medical degree from Hubei University of Chinese Medicine in the People’s Republic of China.